Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Monopar Therapeutics Inc (MNPR)

Monopar Therapeutics Inc (MNPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers GlobeNewswire - Tue Oct 15, 7:00AM CDT

MNPR : 5.50 (-3.68%)
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers GlobeNewswire - Mon Oct 7, 7:00AM CDT

MNPR : 5.50 (-3.68%)
Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments Globe Newswire - Thu Aug 11, 2022

Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe and Enrolling Patients Toward Interim Analysis Anticipated in Q1 2023...

MNPR : 5.50 (-3.68%)
Monopar Therapeutics Reports First Quarter 2022 Financial Results and Recent Program Developments Globe Newswire - Thu May 12, 2022

Validive® Phase 2b/3 VOICE Trial Continues Enrolling Patients Toward InterimCamsirubicin Phase 1b Dose-Escalation Trial Clears 3rd Dose Level, Now...

MNPR : 5.50 (-3.68%)
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments Globe Newswire - Thu Mar 24, 2022

Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe Camsirubicin Phase 1b Dose-Esclation Trial Clears 2nd Dose Level and...

MNPR : 5.50 (-3.68%)
Monopar to Present at the 34th Annual Roth Conference and Maxim’s 2022 Virtual Growth Conference Globe Newswire - Tue Mar 8, 2022

WILMETTE, Ill., March 08, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on...

MNPR : 5.50 (-3.68%)
Monopar Announces Clinical and Preclinical Program Updates Globe Newswire - Tue Feb 15, 2022

Validive Phase 2b/3 VOICE trial now open at 43 sites; active and enrolling in US and EU Open-label Phase 1b camsirubicin trial: early signs of clinical...

MNPR : 5.50 (-3.68%)
Monopar to Present at the H.C. Wainwright BioConnect Conference Globe Newswire - Fri Jan 7, 2022

WILMETTE, Ill., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on...

MNPR : 5.50 (-3.68%)
Monopar Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial Globe Newswire - Wed Dec 8, 2021

WILMETTE, Ill., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on...

MNPR : 5.50 (-3.68%)
Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments Globe Newswire - Fri Nov 12, 2021

First Patients Dosed in Camsirubicin Phase 1b Clinical Trial in U.S.Validive® Phase 2b/3 VOICE Trial Cleared to Enroll in Europe andon Track for Reaching...

MNPR : 5.50 (-3.68%)

Barchart Exclusives

Use Stochastics to Extract a 23% Yield from AMD Stock Options This Week Barchart - 12 minutes ago
Through a risky but enticing iron condor, investors can potentially grab some income in just one week. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot